Shanghai Haohai Biological Reports Full-Year Income Retreat Amid VBP Pressures

The retreat in full-year income reported by Shanghai Haohai Biological Technology Co., Ltd. signals a critical inflection point for one of China’s most prominent biomedical materials manufacturers. As a leader in the fields of ophthalmology, medical aesthetics, and wound care, Haohai has long benefited from the rapid expansion of China’s private healthcare sector. However, the latest financial results indicate that the company is now grappling with a more complex operating environment, characterized by aggressive regulatory intervention and a maturing consumer market. This downturn in profitability is not merely a company-specific setback but serves as a broader indicator of the structural shifts currently reshaping the Chinese medical device industry.

A primary driver of the income decline is the continued expansion and intensification of the National Healthcare Security Administration’s (NHSA) Volume-Based Procurement (VBP) program. This policy, which aims to reduce healthcare costs by consolidating purchasing power at the provincial and national levels, has significantly impacted Haohai’s core ophthalmology business. The company’s intraocular lenses (IOLs), which are essential for cataract surgeries, have been subject to multiple rounds of competitive bidding. While these tenders ensure high sales volumes, they do so at the cost of substantial price concessions. For a company like Haohai, which has historically relied on high margins from its biomedical materials, the challenge lies in scaling production fast enough to offset the per-unit revenue loss. The VBP effect has effectively commoditized what were once high-value specialty products, forcing a reassessment of the company’s revenue mix.

“

A primary driver of the income decline is the continued expansion and intensification of the National Healthcare Security Administration’s (NHSA) Volume-Based Procurement (VBP) program.

In the medical aesthetics segment, Haohai is facing a different but equally daunting set of challenges. The market for hyaluronic acid dermal fillers and other light aesthetic procedures in China has become increasingly saturated. Domestic competitors have rapidly improved their manufacturing capabilities, leading to a surge in low-cost alternatives that challenge Haohai’s market share. To defend its position, the company has had to significantly increase its selling and distribution expenses, investing heavily in marketing and physician education. These rising costs, coupled with a more cautious consumer spending environment, have placed additional pressure on net margins. The shift in consumer behavior toward more cost-effective treatments suggests that the era of effortless growth in the aesthetics sector may be coming to an end, requiring a more nuanced approach to brand loyalty and product differentiation.